ACTIVATE YOUR
OWN DEFENSE

Latest news headline

MVX-ONCO Explained

06.07.2022

Interview with Mrs Ksenija Pavletic, MaxiVAX’s Chairwoman and Prof Nicolas Mach MaxiVAX’s Co-founder and Chief Scientific Officer in the Entreprise Romande, a publication by the “Fédération des Entreprises Romandes Genève” (in French).

MaxiVAX has completed a Phase I clinical trial, whereby a total of 34 patients were treated. The results of this clinical trial demonstrated that MaxiVAX’s personalised immunotherapeutic treatment is feasible, safe and well tolerated.

MaxiVAX’s on-going Phase II Head and Neck clinical trial shows promising results. The interim data review shows 75% of patients reaching the 6 months survival endpoint, which is above the initial target of 50% of patients reaching 6 months survival. With these promising results, MaxiVAX plans to complete this study by the end of 2023.

While remaining optimistic, Mrs Ksenija Pavletic shares her insights on the financing challenges that many start-ups such as MaxiVAX often face. She also adds that it would require approximately four more years to bring MaxiVAX’s immunotherapeutic product to the market.

Entreprise Romande : Interview MaxiVAX

 

14.06.2022

MaxiVAX will be participating and presenting a scientific poster at the Immune Responses in Cancer Infection (IRCI) meeting, Lyon on 15- 17th June. The IRCI2022 is organized by researchers from two leading centres in Lyon, the CIRI and CRCL.

The IRCI meeting will bring together international prominent scientists and clinicians to discuss their recent immunological findings in fundamental and clinical research.

Read more: Immune Responses in Cancer Infection meeting

Poster MaxiVAX IRCI meeting

 

12.05.2022

MaxiVAX will participate in the European Oncology Partnering Convention, a two-day event entirely dedicated to open innovation in Oncology – Bordeaux, France on 12 -13 May, 2022.

Read more: European Oncology Partnering Convention

 

07.04.2022

Interview with Prof Nicolas Mach, Co-founder and Chief Scientific Officer in Switzerland’s “Bilan” Magazine (in French). Prof Mach explains about MVX-ONCO-1 and the Phase II clinical trial conducted in 4 sites in Switzerland, aimed at tackling Head and Neck Squamous Carcinoma (HSNCC). All patients enrolled in the study have confirmed diagnosis of HNSCC, state III/IV and have previously failed several courses of standard therapy. Preliminary results of this clinical trial are very encouraging and MaxiVAX intends to complete this study in the following 6 to 9 months.

MaxiVAX aims to raise capital to further advance clinical studies of the company’s lead therapeutic products in other solid cancers. A partnership with Minaris Regenerative Medicine, a Contract Development and Manufacturing and Organisation, has been concluded, to scale-up the manufacturing of MaxiVAX’s lead product MVX-ONCO-2.

Bilan : MaxiVAX veut traiter tous les cancers

 

5.04.2022

Prof. Nicolas Mach, co-founder and CSO of MaxiVAX, presented the bench to bedside development of MVX-ONCO at HUG’s Café de l’Innovation.

Read more (French) : HUG café de l’innovation

 

09.03.2022

Geneva – March 3rd, 2022 – MaxiVAX will attend the RNA Leaders World Congress live in Basel, March 16-17, 2022. The event is a gathering of leading pharmas and biotechs as well as academic institutions that develop RNA medicines. MaxiVAX will participate on the partnering platform.

 

27.01.2022

MaxiVAX announces the completion of enrolment into the MVX-ONCO-1 phase I – part 3 – clinical trial in Advanced Solid Tumors with encouraging safety and efficacy signals.

Geneva – January 27, 2022 – MaxiVAX announced today the completion of enrolment into the phase I trial of MVX-ONCO-1 in advanced solid tumors. The study’s part 3 was an extension to recruit in total 35 patients following positive safety profile and encouraging efficacy signals from part 1&2. The initial phases of the study were completed in 2016 and 2018 respectively, and were designed to enroll patients with rare types of advanced solid tumors in order to collect additional safety, efficacy and translational research data.

MaxiVAX is now very proud to announce that the last patient started its treatment in October 2021 and will end the short-term follow-up in March 2022. The company plans to publish the results of this study shortly thereafter.

 

19.10.2021

MaxiVAX to take over the sponsorship of SAKK 11/16 phase II clinical study in HNSCC.

Geneva – October 19, 2021 – MaxiVAX announced today that the company has taken over the sponsorship of SAKK 11/16 phase II clinical study in patients with Head & Neck Squamous Cell Carcinoma. The long lasting and appreciated relationship with SAKK will continue, as SAKK will remain involved in the context of a Sponsor-CRO collaboration.

As the new sponsor of SAKK 11/16, MaxiVAX held an Investigator meeting on the 6th of October 2021. The highly awaited event saw the active participation of 4 investigators and clinical study staff from our 4 recruiting sites (Lausanne, Zurich, St. Gallen and Geneva).

The investigator meeting presented an excellent opportunity for the participants to have discussions on the latest protocol amendment and challenges faced by each site. It drew valuable feedback from the floor and the inputs from the investigators shed new insights on the scientific and operational aspects of the trial. The session resulted in an alignment and commitment from the CRO, the Sponsor and the investigators. MaxiVAX would like to thank the participants, and especially the investigators and the clinical study staff for their involvement.

This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 880194.

 

06.10.2021

MaxiVAX to advance its second-generation personalized immunotherapy – MVX-ONCO-2 – to studies in solid tumors.

Geneva – October 6, 2021 – MaxiVAX announced today that the company has filed a Clinical Trial Application for a multicenter phase I study of MVX-ONCO-2 in patients with advanced solid tumors. This advancement is the result of several years of development and close collaboration with experts in immuno-oncology and cell encapsulation technologies.

MVX-ONCO-2 follows the scientific principles of MVX-ONCO-1, MaxiVAX’ first asset in clinical development. The phase I study evaluating the safety, tolerability, and efficacy of MVX-ONCO-1 in patients with advanced solid tumors will be completed in Q1-2022. The encouraging safety and efficacy signals observed in this open label study led to the development and initiation of the phase II PoC study in Head & Neck Squamous Cell Carcinoma (SAKK 11/16), which is currently enrolling patients.

By developing MVX-ONCO-2, a second asset to enter clinic in Q2 2022, MaxiVAX has created a new cell encapsulation technology with platform capabilities and optimized features for long term GMCSF delivery in vivo. The company believes that this technology will further improve the efficacy profile of MVX-ONCO-1 without compromising its very good safety profile. A total of 6 patients with advanced melanoma (3) and advanced solid tumors (3) will be enrolled in this phase Ia study of MVX-ONCO-2.

MaxiVAX is also investigating expanding the use of its encapsulation technology to potentially bring therapeutic solutions to the extensive unmet medical need in other chronic disease such as inherited bleeding disorders or lysosomal storage diseases.

 

27.05.2021

CELL ENCAPSULATION COULD ENHANCE ANTIVIRAL VACCINES

Immunotherapy techniques developed in oncology to combat cancerous cells have great potential for fighting viruses. A research team from the University Hospitals of Geneva (HUG) and the University of Geneva (UNIGE), in Switzerland, in collaboration with MaxiVAX, a spinoff of both institutions, developed an innovative technology called « cell encapsulation ». Originally designed to stimulate immunity to fight cancer, the COVID-19 pandemic motivated the scientists to broaden the scope of their technology to test its effectiveness against viruses. The first results of a pre-clinical study are very encouraging and can be discovered in the journal Vaccines.

 English Français

22.02.2021

MaxiVAX and Minaris Regenerative Medicine Enter into a Manufacturing Partnership

GENEVA, Switzerland and MUNICH, Germany – Feb 22, 2021 — MaxiVAX SA, a private Swiss clinical-stage biotech company developing novel anti-cancer vaccines, and Minaris Regenerative Medicine GmbH (“Minaris”), a leading contract development and manufacturing service provider for the cell and gene therapy industry, have entered into a manufacturing agreement for MVX-ONCO-2, a cell-based immunotherapy for the treatment of cancers such as chordoma, head and neck, and other solid tumors.

 English Français Deutsch

This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 880194.

02.06.2020

COVID-19

Geneva study against SARS-COV-2 gets underway

Geneva University Hospitals (HUG), the University of Geneva (UNIGE), the Infectious Disease Research Centre at Laval University in Quebec (Canada) and MaxiVAX – a Geneva-based company specialising in biotechnology – are working together to develop a SARS-CoV-2 vaccine. This joint research programme aims to create a vaccine combining an immunostimulator and a specific coronavirus target, namely the spike surface protein. This is administered by intradermal injection with the immunostimulator, whose role is to produce an adjuvant capable of stimulating the immune system. It is implanted under the skin via cell encapsulation, a technology that is already undergoing Phase II clinical tests led by HUG in collaboration with MaxiVAX in the area of cancer immunotherapy.
The first pre-clinical tests for perfecting the vaccine will be carried out on mice in the coming weeks. If preliminary tests prove encouraging, a clinical trial could be set up in the near future.

 English Français

26.11.2019

MaxiVAX awarded €2,785,000 European Commission grant and announces successful closing of its Series B 2 round for an amount of CHF 5 million

  • MaxiVAX wins grant among 94 projects funded out of 2,015 applications
  • Closing of Series B 2 round of CHF 5 million from new and existing investors
  • Funds used for Phase 2 cancer programs

MaxiVAXSA, a private Swiss clinical-stage biotech company developing novel anti-cancer vaccines, announced today that it had been awarded a European Commission grant of €2,785,000, thanks to the Horizon 2020EIC Accelerator Programme.MaxiVAX was among 94 funded projects out of 2,015 applicants, thereby ranking among the top 4% of high-tech companies.

The company also reported the successful closing of a Series B 2 roundof CHF 5 million from new and existing investors, whose continuing support the company is particularly grateful.

English  Français

This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 880194